Source: Annual Congress 2013 –Studies of asthma in man
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Pavord, P. Mueller, C. Lassen, T. Casale, K. M. Beeh (Leicester, United Kingdom; Schlieren, Switzerland; Omaha, United States Of America; Wiesbaden, Germany). Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma. Eur Respir J 2013; 42: Suppl. 57, 3156

Member's Comments

No comment yet.

Related content which might interest you: Benralizumab effect on blood basophil counts in adults with uncontrolled asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis Source: International Congress 2015 – Epidemiological studies of asthma and allergy Year: 2015 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016 Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Effect of vitamin d therapy on the pulmonary functions in pediatric asthma and allergic rhinitis Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 The association between clinical features of asthma and impact of one-year sublingual immunotherapy on immunological system of atopic children Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Elevated blood eosinophil is a risk factor for future exacerbations in asthmatic children Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 One-year sublingual immunotherapy in asthmatic children do not influence on basophil’s CD203c stimulated and spontaneous expression Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015